Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Modified Release AFQ056 for PD-LID
NCT01491529Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of mavoglurant in levodopa-induced dyskinesia (LID), sponsored by Novartis. Started Apr 2012; status: completed.
02
Drugs
mavoglurant
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT01491529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01491529.